(Reuters) – Drugmaker Novartis has been hit by a slowdown in emerging markets, particularly in China, where previously double-digit growth has decelerated to mid-single digits, Chief Executive Joe Jimenez said in an interview with CNBC on Friday.
Jimenez’ comments echoed concerns expressed on Thursday by U.S. Federal Reserve Chair Janet Yellen, who said the outlook in emerging markets including China have led to volatility.
Despite the increasing risks, Jimenez said the Swiss company was not pulling back from emerging markets, rather relying on the strength of generics in China to drive business growth.
“So we are not pulling back. We’re in these markets for the long term. We are going to live through the volatility,” he said.
“We have seen a bit of a slowdown in emerging markets particularly China but in our business that means moving from mid-double digit growth rates to now in the mid-single digit growth rates,” he added. “If you think about the global healthcare market maybe growing at 2 or 3 percent this is still incremental growth.”
Novartis shares fell further after Jimenez’ comments, and were down 1.1 percent at 0900 GMT.
Novartis was still digesting acquisitions including from its $20 billion asset swap last year with GlaxoSmithKline, which bolstered the Basel-based company’s position in cancer drugs, among others.
Jimenez did not rule out further acquisitions.
“We’re looking at everything that’s out there,” he said. “The reason why Novartis hasn’t moved is that assets are very expensive right now and I think we’re going to hold our powder, we’re going to see what happens in the markets.” ($1 = 0.9573 Swiss francs) (Reporting by John Miller; Editing by Joshua Franklin and Susan Fenton)
Johnson & Johnson has announced that it plans to separate its Consumer Health business, leaving the new Johnson & Johnson to focus on pharmaceuticals and medical devices. Alex Gorsky, current CEO, will become the Executive Chairman of the new Johnson & Johnson. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, will become the new CEO.
Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms applicable across all Novo Nordisk’s therapeutic focus areas.
Naomi predicts that start-ups will continue to take over the healthcare industry, and Big Pharma companies will be forced to adapt to the future by partnering with small tech start-ups, or fade away due to irrelevance. Discover more of industry leader Naomi Fried’s insights as she discusses the future of healthcare with Andrew Kris of Borderless